Filtros de búsqueda

Lista de obras de Federico Cappuzzo

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.

artículo científico

A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

artículo científico publicado en 2006

ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.

artículo científico publicado en 2014

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

artículo científico publicado en 2011

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

artículo científico publicado en 2015

Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer

artículo científico publicado en 1995

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

artículo científico publicado en 2014

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treat

artículo científico publicado en 2015

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

artículo científico publicado en 2014

Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature?

artículo científico publicado en 2010

Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.

artículo científico publicado en 2014

Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance

artículo científico publicado en 2006

Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study

artículo científico publicado en 2015

Ceritinib for the treatment of non-small cell lung cancer

artículo científico

Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

artículo científico publicado en 2015

Clinical experience with gefitinib: an update

artículo científico publicado en 2006

Clinical implications of MET gene copy number in lung cancer

scientific article published on February 2010

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

artículo científico publicado en 2007

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

scientific article published on October 2010

Consequences of targeted treatments for second-line therapy

scientific article published on October 2010

Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.

artículo científico publicado en 2011

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

artículo científico publicado en 2015

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly

artículo científico

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

artículo científico publicado en 2014

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

artículo científico publicado en 2007

EGFR FISH versus mutation: different tests, different end-points.

artículo científico publicado en 2008

EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation

artículo científico publicado en 2012

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

article

EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center

artículo científico publicado en 2016

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

artículo científico publicado en 2009

EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?

artículo científico

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

artículo científico publicado en 2011

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

artículo científico publicado en 2010

Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer

artículo científico publicado en 2004

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

artículo científico publicado en 2016

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).

artículo científico publicado en 2004

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

artículo científico publicado en 2009

Emerging drugs for non-small cell lung cancer

artículo científico publicado en 2003

Emerging drugs for small cell lung cancer--an update

artículo científico

Emerging drugs for small-cell lung cancer

scientific article published on December 2009

Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

artículo científico publicado en 2006

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

artículo científico publicado en 2005

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

artículo científico

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).

artículo científico publicado en 2003

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

artículo científico publicado en 2010

Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?

artículo científico publicado en 2005

Erlotinib in the first-line treatment of non-small-cell lung cancer

artículo científico

Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials

artículo científico publicado en 2015

Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study

artículo científico publicado en 2013

Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma

artículo científico publicado en 2005

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

artículo científico publicado en 2016

Experience with erlotinib in the treatment of non-small cell lung cancer

artículo científico

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

artículo científico publicado en 2014

Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy

scientific article published on 21 May 2020

First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.

artículo científico publicado en 2012

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

artículo científico publicado en 2014

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

artículo científico

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

artículo científico publicado en 2010

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

artículo científico publicado en 2014

Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.

artículo científico publicado en 2010

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues

artículo científico publicado en 2011

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

artículo científico publicado en 2011

Gefitinib for non-small-cell lung cancer treatment

artículo científico

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

artículo científico publicado en 2004

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

artículo científico publicado en 2003

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

artículo científico publicado en 2008

Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study

artículo científico publicado en 2003

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

artículo científico publicado en 2008

Gemcitabine in non-small cell lung cancer

artículo científico publicado en 2002

Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

artículo científico publicado en 2011

HER2 and lung cancer

artículo científico

HER2 in solid tumors: more than 10 years under the microscope; where are we now?

artículo científico publicado en 2014

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer

artículo científico publicado en 2006

Impact of biomarkers on non-small cell lung cancer treatment

artículo científico publicado en 2010

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

artículo científico publicado en 2005

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

artículo científico publicado en 2012

Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.

artículo científico publicado en 2011

Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.

artículo científico publicado en 2009

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib

scientific article published on 06 April 2006

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

artículo científico publicado en 2012

Irreversible EGFR-TKIs: dreaming perfection

artículo científico publicado en 2013

Is FISH floating or still swimming in the lung cancer ocean?

artículo científico publicado en 2011

Is gemcitabine cost effective in cancer treatment?

artículo científico publicado en 2007

Let-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features

artículo científico publicado en 2013

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

artículo científico publicado en 2016

Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial.

artículo científico publicado en 2007

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

artículo científico publicado en 2007

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

scientific article published on 03 October 2008

MET overexpression and gene amplification in NSCLC: a clinical perspective.

artículo científico publicado en 2013

MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib

scientific article published on April 2009

Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology

artículo científico publicado en 2012

Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.

artículo científico publicado en 2014

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

artículo científico publicado en 2016

Management of NSCLC: focus on crizotinib

artículo científico publicado en 2014

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

artículo científico publicado en 2014

Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP)

artículo científico publicado en 2010

MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies

artículo científico publicado en 2013

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

artículo científico publicado en 2006

Nit-picking around second line in EGFRwt NSCLC: just an academic effort.

artículo científico publicado en 2014

Onartuzumab in lung cancer: the fall of Icarus?

scientific article published on 30 March 2015

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer

artículo científico publicado en 2016

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

artículo científico publicado en 2014

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

artículo científico publicado en 2008

Pharmacotherapy targeting the EGFR oncogene in NSCLC.

artículo científico

Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.

artículo científico publicado en 2015

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer

artículo científico publicado en 2005

Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer

artículo científico publicado en 2003

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

artículo científico publicado en 2009

Primary pulmonary meningioma

scientific article published on 19 May 2008

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

artículo científico publicado en 2008

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer

artículo científico publicado en 2014

Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer

artículo científico

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

artículo científico publicado en 2007

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer

artículo científico publicado en 2011

Protein kinase inhibitors to treat non-small-cell lung cancer

artículo científico publicado en 2014

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

artículo científico publicado en 2016

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

artículo científico publicado en 2014

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

artículo científico publicado en 2012

Rare mutations in non-small-cell lung cancer

artículo científico

Role of gemcitabine in cancer therapy

artículo científico publicado en 2005

Should every lung cancer patient be tested for EGFR mutation?

artículo científico publicado en 2006

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.

artículo científico publicado en 2011

Strategies for improving outcomes in NSCLC: a look to the future

artículo científico

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

artículo científico publicado en 2011

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

artículo científico publicado en 2016

Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR.

artículo científico publicado en 2011

Targeted therapy for NSCLC with driver mutations

artículo científico

Targeting MET in NSCLC: looking for a needle in a haystack

artículo científico publicado en 2014

Targeting c-MET in the battle against advanced nonsmall-cell lung cancer

artículo científico

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.

artículo científico

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology

artículo científico publicado en 2013

Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis

publication published on 23 November 2021

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases

artículo científico publicado en 2003

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance

artículo científico

microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers

artículo científico publicado en 2015

p95HER2 truncated form in resected non-small cell lung cancer

artículo científico publicado en 2012

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda